Alpine Global Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Alpine Global Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$442K	Buy	1,467 +550	+60%	+$166K	0.07%	117
2026 Q1	$303K	Sell	917 -1,145	-56%	-$390K	0.05%	147
2025 Q4	$820K	Buy	+2,062	New	+$913K	0.18%	77
2022 Q1	–	Sell	-6,334	Closed	-$1.07M	–	445
2021 Q4	$1.07M	Buy	+6,334	New	+$1.18M	0.16%	119
2017 Q4	–	Sell	-7,410	Closed	-$871K	–	188
2017 Q3	$871K	Buy	+7,410	New	+$632K	0.25%	62

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alpine Global Management's ALNY Position: Q2 2026 in Review

Alpine Global Management increased its Alnylam Pharmaceuticals (ALNY) stake by 60% in Q2 2026, buying an estimated $166K and bringing the position to 1,467 shares worth $442K. The position accounts for 0.07% of the portfolio, ranked #117.

Alpine Global Management first reported a position in ALNY in Q3 2017 and has held it in 5 quarters since. The position peaked at $1.07M in Q4 2021. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Alpine Global Management held 1,467 shares of Alnylam Pharmaceuticals worth $442K as of Q2 2026.
Alpine Global Management bought 550 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $166K.
Alnylam Pharmaceuticals made up 0.07% of Alpine Global Management's portfolio in Q2 2026, its #117 holding.
Alpine Global Management first reported a position in Alnylam Pharmaceuticals in Q3 2017 and has held it in 5 quarters since.
Alpine Global Management's Alnylam Pharmaceuticals position peaked at $1.07M in Q4 2021.
790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Alpine Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.